Posted by Michael Wonder on 11 Feb 2025
Biohaven announces FDA acceptance and priority review of troriluzole new drug application for the treatment of spinocerebellar ataxia
11 February 2025 - Troriluzole demonstrated a 50-70% slowing of spinocerebellar ataxia disease progression on the primary and secondary outcome measures at the 3 year endpoint in a real-world evidence study.
Biohaven today announced that the US FDA has accepted for review the Company's new drug application for troriluzole for the treatment of adult patients with spinocerebellar ataxia and has granted priority review.
